Onset of Neuromuscular Blockade (NMB)
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 21-007425
NCT ID: NCT05120999
About this study
The primary aim of this study is to compare the time difference from neuromuscular blocking agent (NMBA) administration to neuromuscular blockade (NMB) onset defined as a train-of-four count (TOFC) equal to 0, utilizing electromyographic (EMG) vs. acceleromyographic (AMG) neuromuscular monitors while intubating conditions are being evaluated.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Age ≥ 18 years old.
- Patients willing to participate and provide an informed consent.
- Patients undergoing elective surgical procedures that require use of NMBA agents (rocuronium) administered intraoperatively.
Exclusion Criteria:
- Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
- Patients with systemic neuromuscular diseases such as myasthenia gravis.
- Patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents; i.e., severe renal impairment or end-stage liver disease.
- Patients having surgery that would involve prepping the arm into the sterile field.
- Patients receiving a rapid sequence induction.
Eligibility last updated 8/12/21. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Jacksonville, Fla.
Mayo Clinic principal investigator Johnathan Renew, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available